Shots:
In the wake of International Labour Day, PharmaShots presents a detailed take on the recent layoffs in the Pharmaceutical Sector with an illustrative graphical analysis
Like any sector, the pharmaceutical industry operates on some nuance and intricate aspects that ensure smooth operations. Factors like digitalization, patent expiry, growing competition, and others put direct or…
Shots:
The EMA approved 4 New Chemical Entity (NCE) and 5 Biologic Drugs in March 2023, leading to treatments for patients and advances in the healthcare industry
In March 2023, the major highlights drugs were Reblozyl’s Approval for anemia in adult patients with non-transfusion-dependent beta thalassemia, Pombiliti for late-onset pompe disease
PharmaShots has compiled a…
Shots:
The US FDA approved 6 NDAs and 1 BLA in March 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2023
In March 2023, the major highlights drugs were, Tafinlar + Mekinist approval for BRAF V600E low-grade glioma, Zynyz for metastatic or…
Shots:
With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing
While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
Shots:
Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. However, the previous year was difficult for biopharma companies as the segment saw multiple insolvencies.
Amidst all kinds of obstacles, many companies have sustained themselves to meet the market…
Shots:
The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory gout
Starting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. The first quarter of the year also showcases…
Shots:
Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions
Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Some companies accept the offered period and open doors to biological drugs or biosimilars. In…
Shots:
Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnership
To tackle such scenarios, companies are cautious enough to make backup plans beforehand…
Shots:
Trailblazing, inspiring, and emancipating, women’s contribution to society is highly significant. By breaking the shackles of orthodox social customs, they made an indistinguishable place in society that we all should be proud of
Every year on the 8th of March, the world celebrates International Women’s Day as a day of observance for women’s triumph in the social,…
Shots:
The EMA approved 6 New Chemical Entity (NCE) and 6 Biologic Drugs in December 2022, leading to treatments for patients and advances in the healthcare industry
In December 2022, the major highlights drugs were Pluvicto’s approval for progressive PSMA+ metastatic castration resistant prostate cancer, Dupixent for Prurigo Nodularis
PharmaShots has compiled a list of…

